PDX1 and Cachexia: It is based on the 3x-transgenig KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (KPC) mutants (Kras: Kirsten Rat Sarcoma, Trp53: Transformation-related protein 53, Pdx-1-Cre: Pancreatic and duodenal homeobox 1-cyclization recombination) and commonly utilized for PDAC research and preclinical therapeutic testing, since it mimics well clinical features of human PDAC, such as metastatic pattern (liver 80%, lung 50–60%, adrenal gland 20%, and peritoneum 20–30%), ascites and, importantly, of cachexia development [44,45,46].